DBV Technologies Shares Dip Despite Optimistic Phase 3 Trial Results

DBV Technologies shares are trading lower despite positive results from its Phase 3 VITESSE trial, with optimistic ratings from firms like Citizens, H.C. Wainwright, Guggenheim, and Cantor Fitzgerald, who raised their price targets to $45, $40, $51, and $48 respectively.